The Filing Desk

Zevra Therapeutics vs Zymeworks

Zevra Therapeutics ZVRA · Zymeworks ZYME · Pharmaceuticals

Zevra Therapeutics reported revenue of $106 million in fiscal 2025, about the same as Zymeworks' $106 million in fiscal 2025. Zevra Therapeutics' revenue grew 350.9% in its latest year, and Zymeworks' grew 38.9%. Zevra Therapeutics had an operating margin of -59.1%, against -87.3% at Zymeworks. Free cash flow was −$2 million at Zevra Therapeutics and −$35 million at Zymeworks.

Side by side

Zevra TherapeuticsZymeworks
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$106M$106M
Revenue growth350.9%38.9%
Revenue growth a year, last 5 years51.6%22.1%
Gross margin——
Operating margin−59.1%−87.3%
Net margin78.2%−76.6%
Free cash flow−$2M−$35M
Free cash flow margin−2.3%−32.6%
Return on capital−218.8%—
Net debt to EBITDA——
Dividends and buybacks$0M$42M
Change in diluted share count23.8%−0.6%
Last close$9.08$26.24
P/E at the last close7.6×50.5×
Insider trades, last 12 months—sold $4.7 million
Piotroski F-score5 of 8—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Zevra TherapeuticsZymeworks
Operating margin
Percent of revenue
Zevra TherapeuticsZymeworks
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Zevra TherapeuticsZymeworks

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Zevra Therapeutics and Zymeworks pages.